Introduction
Decreases in blood pressure and blood volume are potent stimuli for vasopressin and oxytocin (VP/OT) release from the posterior pituitary (33). Information about decreases in blood pressure and/or volume is transmitted to the magnocellular VP and OT neurons in the paraventricular (PVN) and supraoptic nuclei (SON) via the A1 catecholamine pathway which utilizes ATP and norepinephrine as neurotransmitters (6) .
Postural changes induce acute elevations in plasma VP (21) while prolonged decreases in blood pressure and/or volume can elicit increases in plasma VP/OT that are sustained for hours to days (3, 15, 29) . The absence of these sustained elevations in plasma VP leads to cardiovascular collapse in hemorrhagic and septic shock (24, 27, 30) .
Simultaneous exposure of explants of the hypothalamo-neurohypophyseal system (HNS) to ATP and phenylephrine [(PE) to mimic noradrenergic activation of α1-receptors (α1-AR)] results in conversion of the small, transient response elicited by either agent alone to a larger and sustained elevation in VP/OT release (20) . This synergistic effect of ATP and PE may be responsible for the sustained increase in VP secretion that occurs during chronic hypotension and/or hypovolemia. Therefore, it is important to determine the mechanism(s) responsible for the sustained response.
Although evidence exists for involvement of purinergic mechanisms in the neural lobe (41) as well as presynaptic and glial actions of ATP and norepinephrine (9, 12, 13), we have shown that the site of ATP+PE synergism is not in the neural lobe (38) and that the synergism is not prevented by ionotropic or metabotropic glutamate receptor antagonists (38) . Thus, the synergism cannot be explained by PE stimulation of glutamate release or changes in AMPA receptor trafficking. Also, it does not reflect ATP conversion to adenosine (37) . Therefore, ATP+PE-induced synergism of VP/OT release appears to involve receptors on the perikarya of VP and OT neurons. Extracellular ATP activates both ionotropic (P2X) and metabotropic (P2Y) purinergic receptors. There are 7 P2X-R subtypes that are coded by different genes [P2X1-7; (26)], and there are 8 P2Y-R subtypes that are 7 transmembrane, G protein coupled receptors coupled to either Gq or Gi (43) . Both types of receptors contribute to the ATP-induced responses of SON neurons: ATP induces both calcium influx and release of stored calcium (39) . The release from stores reflects activation of P2Y1-Rs, because in the absence of external Ca ++ , a P2Y1-R antagonist, MRS2179, prevents the ATP-induced increase in [Ca ++ ] i (39) . The calcium influx requires activation of P2X-Rs, because 10µM PPADS (pyridoxal-phosphate-6-azophenyl-2', 4'-disulphonic acid)
prevented ATP-induced Ca ++ influx, but it did not prevent ATP-induced release of calcium from intracellular stores (40) . This effect of PPADS can be attributed to its effects on P2X-Rs, because although at ≥30µM, PPADS blocks some P2Y-Rs, at 10µM, it is selective for rat P2X2, 3, and 2/3-Rs (25). This subtype selectivity exists in SON neurons, because, as stated above, 10µM PPADS did not block ATP-induced release of stored calcium (40) . PPADS (10µM) also blocked the ATP+PE-induced extended elevation in [Ca ++ ] i as well as both ATP-induced VP/OT release and the synergistic ATP+PE-stimulated VP/OT release from HNS explants (20) . Although a P2Y1-R agonist, 2-Me-SADP, stimulates VP/OT release from HNS explants, the P2Y1-R antagonist, MRS2179, does not block ATP-induced VP/OT release (36 As both values far exceed the highest ratio achieved by any agent studied, the peak responses obtained are not limited by the maximum detectable change in the 340/380 ratio. The ratio data is presented as % of the basal 340/380 ratio for each cell (see below).
Data analysis. Magnocellular neurons were identified by the size of the cell body (>25 µm in diameter) and their proximity to optic chiasm. In previous studies some neurons meeting these criteria were also identified as VP neurons based on their response to VP (7, 40 Hormone release from HNS explants. Explants were positioned individually in perifusion chambers having a 500 µl volume, and perifused with F12 nutrient mixture supplemented with 20% fetal calf serum, 1 mg/ml glucose, 100 U/ml penicillin, 100 µg/ml streptomycin, 1x10 -4 M bacitracin, and a final osmolality of 300 mosmol/kg H 2 O.
The medium is warmed (37°C) and gassed (95% O 2 , 5% CO 2 ) immediately before entering the chamber. The perifusion rate was 2.0 ml/hr. Agonists and antagonists were added to the perifusion medium prior to the pump. The time that the agents reached the explant is indicated either by an arrow or bar in the figures. All agonists and antagonists were obtained from Sigma-Aldrich or Tocris Bioscience (e.g. MRS2791) and used at EC 50 or a concentration selective for the receptor subtype of interest as determined from the reference provided. Outflow from the chambers was collected individually in timed fractions using a six-place fraction collector housed in a refrigerator (4°C) to reduce enzymatic degradation of the hormones. VP and OT concentration in these samples was determined by radioimmunoassay as described previously (44) . Although VP and OT release from suprachiasmatic and SON dendrites contributes to the hormone released from HNS explants (8, 14) , hormone released from the posterior pituitary far exceeds that from the hypothalamic portion of the explants and overwhelms the impact of any changes occurring from other sources (14) . Hormone release from HNS explants is tetrodotoxin sensitive suggesting that it occurs in response to action potential propagation from SON to the neural lobe (35) .
Data analysis. Explants were allowed to equilibrate for 4-5 hours. VP/OT release was determined during the hour immediately preceding exposure to drugs. Hormone release in response to experimental manipulations is expressed as a % of this initial basal release for each explant. Basal release for the explants included in these studies was 60.99±6.8 pg/ml for VP and 63.11±7.06 pg/ml for OT (Mean±SEM). ANOVA with repeated measures followed by post hoc simple main effects analysis was performed on log-transformed data to evaluate changes in hormone release and to compare responses between groups.
Immunohistochemistry. Male Sprague-Dawley rats (250-300 gms) were anesthetized with Avertin (1 ml/100g body weight delivered IP) and the brain was min. Protein concentrations of the extracts was determined using Biosciences CB-X Protein Assay Kits. Extracts were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose, blocked with 5% nonfat milk, and incubated with primary-antibody (P2X2: Sigma, rabbit affinity purified, 1:250; P2X7: Sigma, rabbit affinity purified, 1:30K, immunogen aa 576-595) in 5% nonfat milk-PBS overnight at room temperature. The nitrocellulose blot was washed 3X for 10 min. in 0.1% Tween followed by 3X PBS rinses and incubated with peroxidase conjugated donkey anti-rabbit IgG (1:5000) for 2 hrs at room temperature. Immunoreactivity was detected using the Pierce Supersignal West Femto Kit. Preabsorption of the antibody with the peptide immunogen eliminated reactive bands.
Co-immunoprecipitation of P2X2 and P2X3-R. SON tissue fragments were prepared as described for WB analysis. Protein extracts (~100-500ug) were incubated with P2X3-R antibody (1-3 µg, Neuromics, guinea pig, immunogen a.a. 383-395). The immunocomplexes were captured on protein A/G Plus agarose beads (Santa Cruz) by gently rocking on an orbital shaker overnight at 4°C. Immunocomplexes were dissociated from the beads by boiling in Laemmli buffer and β-mercaptoethanol. The beads were removed by centrifugation, and the supernatant analyzed by SDS-PAGE (7.5%) gel electrophoresis and WB with P2X2 antibody as above.
Results

Identification of P2X2-R as the subtype responsible for ATP-induced Ca ++ influx
and VP/OT release.
As described in the introduction, our previous studies with 10µM PPADS implicated P2X2, 3, and/or 2/3-R subtypes in the response to ATP alone and in the initial response to ATP+PE (20, 39, 40) . We now provide further support for a role for P2X2-Rs (Fig 2A,B) , and a P2X3 and 2/3-R selective antagonist, A317491 [300 nM; EC 50 =10-300nM (18, 23)], did not alter the Ca ++ response to ATP or ATP+PE (Fig 2C,D) .
Similarly, A317491 (300 nM), did not alter the Ca ++ response to ATP or ATP+PE (Fig   2C,D) . Since simultaneous exposure to ATP+PE converts the transient stimulation of VP and OT release induced by ATP or PE alone into a sustained response, and the P2X2/3
and P2X7-R subtypes are resistant to desensitization by ATP (25), we postulated that one or both of these subtypes might be recruited in the presence of PE and be responsible for the sustained response to ATP+PE. To test this hypothesis, HNS explants were perifused with ATP+PE (100µM each) for 2hrs followed by an additional 3 hr exposure to ATP+PE in the presence of either A317491 (300nM) or Brilliant Blue G (BBG; 1µM).
BBG is a potent antagonist for rat P2X7-R that is highly selective for P2X7-Rs at this concentration (19, 25) . As shown in Fig 3A, the addition of either A317491 or BBG reduced VP release to basal levels. Both agents also abbreviated the ATP+PE-induced stimulation of OT release (Fig 3A' ). This was not due to non-specific inhibition of exocytosis, because BBG did not alter VP release in response to 25mM KCl (data not shown). Thus, both P2X2/3 and 7-Rs are required for the sustained response to ATP+PE.
To assess the time course for dependence of ATP+PE-induced VP/OT release on activation of P2X2/3 and 7-Rs, A317491 and BBG were added to the perifusion medium in advance of ATP+PE. As shown in Fig 3C and D Fig 4A and B) , and BBG did not prevent ATP-induced VP or OT release (Fig 4C and   D Fig 6A) . Thus, the band is not an IgG artifact from the P2X3-R antibody or an artifact from the sepharose beads. This demonstrates that the molecular substrate for participation of P2X2/3 heteromeric receptors exists in SON. This is further supported by evidence for expression of P2X3-R immunoreactivity in SON (Fig 6B, B' ).
In contrast to P2X2 and 3-Rs, immunohistochemistry has not been definitive for localization of P2X7-R in neurons, because currently available P2X7-R antibodies recognize a protein of similar size in several brain regions in P2X7 -/-mice (28, 32). We also found this prominent 75kD protein in microdissected SON tissue from rats and both wild type and knockout P2X7 mice (Fig 7) . However, in addition to that protein, a slightly smaller P2X7-ir protein is present in rat and wild type mouse SON that is absent in P2X7 -/-mice (Fig 7) . This provides evidence for P2X7-R protein in SON, and demonstrates that the P2X7-R mRNA previously detected by RT-PCR in SON neurons (31) is translated into protein. To our knowledge, this is the first definitive molecular evidence for P2X7-R protein in the brain (28, 32).
Is pore formation by P2X7-Rs required?
Another unique characteristic of the P2X2/3 and P2X7-R subtypes is that upon continued exposure to ATP (seconds to minutes), there is a gradual opening of a larger pore, in addition to the ion channel, that allows passage of molecules up to 900 Da (25).
Calmidazolium is an antagonist of P2X7-Rs that blocks the P2X7-R ion channel, but not pore formation (42) . Therefore, to evaluate the importance of P2X7-R-mediated pore formation in the sustained stimulation of VP and OT release by ATP+PE, we assessed the impact of adding calmidazolium to the perifusion medium 2 hours after initiating exposure to ATP+PE. As shown in Fig 8, calmidazolium (10 or 100µM) was ineffective in preventing the sustained stimulation of VP and OT release from HNS explants. Since this is in marked contrast to the prompt and pronounced inhibition induced by BBG, this supports the interpretation that P2X7-R-induced pore formation can sustain the synergistic response to ATP+PE independent of activation of the P2X7-R cation channel.
Is P2Y1-R activation required to initiate the sustained response to ATP+PE?
Since ATP activates G-protein coupled P2Y1-R as well as P2X-Rs in SON neurons (36, 39) , the role of P2Y1-Rs in converting the transient response to a sustained response in the presence of PE was examined by perifusing HNS explants with ATP+PE in the presence or absence of MRS2179, a selective P2Y1-R antagonist (43 The functional involvement of P2X2, P2X2/3, and P2X7-Rs is substantiated by molecular evidence for expression of these receptor subtypes in SON. We provide confirmation of prominent expression of P2X2-R-ir and new evidence for expression of P2X3-R in magnocellular neurons. We also demonstrate, using co-immunoprecipitation, that a portion of the P2X2-R-ir is associated with P2X3-R. To our knowledge, this is the first molecular demonstration of P2X2/3 heteromeric receptors in the brain, and it is corroborated by pharmacological evidence for a functional contribution of P2X2/3-Rs to the sustained stimulation of VP and OT release by ATP+PE. Furthermore, the demonstration of a P2X7-R-ir band in SON that is absent in P2X7 -/-mice supports our pharmacological evidence for BBG sensitive VP/OT responses.
A unique characteristic of several of the P2X-R subtypes is the development of permeability to larger, organic molecules following extended exposure to ATP with P2X7-Rs developing pores large enough to allow small neuroactive agents such as glutamate, GABA, ATP, etc. to exit cells and activate extracellular receptors. The failure of calmidazolium to prevent sustained VP/OT release implicates P2X7-R-induced pore formation, because calmidazolium blocks the P2X7-R-mediated ionic current while leaving the larger permeation pathway unaffected (42) . Further studies are required to evaluate the contribution of pore formation to the response to ATP+PE in SON neurons, because if pore formation is occurring in SON neurons, another challenge will be to identify the molecular nature of a permeation pathway that is not cytolytic.
Potential cellular mechanisms responsible for recruiting the P2X2/3 and 7-R subtypes that mediate the response to ATP in the presence of PE deserve discussion. In our early study demonstrating synergistic stimulation of VP/OT release by ATP+PE, we reported that the sustained response was blocked by actinomycin D and by an inhibitor of protein kinase C, bisindolylmaleimide (20) . The former suggests that the synergistic response is dependent upon new gene expression, and the latter indicates that phosphorylation is required. In the context of the current evidence for recruitment of P2X2/3 and 7-Rs, it is tempting to speculate that this reflects gene transcription and synthesis of these P2X-R subtypes. While this will be pursued in future studies, our finding that A317491 and BBG prevented the synergistic response to ATP+PE when added prior to the ATP+PE suggests that the involvement of these receptors in the response to ATP+PE occurs more rapidly than would be achieved by new receptor 
Perspectives and Physiological Significance
Decreases in blood pressure can induce sustained elevations in plasma VP and OT lasting for at least 90 minutes (29) . In hemorrhagic and septic shock the initial elevations in plasma VP are not sustained in spite of life threatening hypotension which can be reversed by administration of exogenous VP (27) . This relative VP deficiency may reflect failure of the mechanisms that sustain elevated VP secretion in response to hypotension. Norepinephrine modifies responses to other neurotransmitters in thalamus, cortex, and olfactory bulb (1, 11) , but its impact on purinergic responses has not been evaluated in these systems. The potential ability of norepinephrine to convert transient purinergic responses to sustained responses has particular significance to arousal mechanisms, and therefore, the findings presented here have broad implications for CNS function including cognition. not alter this response during the first 2hrs (*p<0.05 for ATP+PE and MRS2179+AP vs control), but subsequently, the response decayed in the MRS2179+AP group such that MRS2179+AP differed statistically from the both ATP+PE and control ($) and then was
